Nemluvio (Nemolizumab)

Nemolizumab, the active ingredient in Nemluvio, is a humanized IgG1 monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of atopic dermatitis and associated pruritus in patients who require targeted immunomodulation.

GNH USA supplies Nemluvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards, provides cold‑chain logistics for biologic stability, and supports regulatory documentation for importers, ensuring reliable access to patients across multiple continents.

Nemluvio (nemolizumab) targets the interleukin‑31 pathway in inflammatory skin disorders. - Atopic dermatitis: reduces skin inflammation and itch severity, improving lesion appearance. - Pruritus associated with atopic dermatitis: alleviates chronic itch and enhances quality of life.

Nemluvio may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site erythema: redness or swelling at the injection site. - Nasopharyngitis: mild upper respiratory infection symptoms. - Headache: transient head discomfort. - Upper respiratory tract infection: cough, sore throat, or congestion. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, swelling, or anaphylaxis. - Severe infections: opportunistic bacterial or fungal infections. - Laboratory abnormalities: elevated creatine phosphokinase levels.

Before initiating therapy, clinicians should consider several safety measures. - Monitor for infection: assess patients for signs of bacterial or fungal infections. - Assess hypersensitivity: inquire about previous reactions to monoclonal antibodies. - Evaluate liver function: perform baseline hepatic tests and monitor periodically. - Use with caution in cardiovascular disease: consider comorbid conditions. - Avoid in patients with known severe allergy to the product components. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nemluvio may interact with other agents that affect immune function.

Major Interactions (Avoid): - Live vaccines: concurrent use can increase risk of vaccine‑derived infection. - Strong immunosuppressants (e.g., high‑dose corticosteroids): may amplify infection risk.

Moderate Interactions (Monitor Closely): - Other biologic agents targeting cytokines: monitor for additive immunosuppression. - Systemic antibiotics: watch for altered infection patterns. - Antifungal therapy: consider potential overlapping immunomodulatory effects.